Peptide Synthesis Services Market Size, Share & Industry Analysis, By Type (Custom Peptide Synthesis, GMP Peptide Synthesis, and Library Peptide Synthesis), By Purity (Crude, Moderate (>70%), High (>95%), Very High (>98%), and Others), By Technique (Solid-Phase Peptide Synthesis, Liquid-Phase Peptide Synthesis, and Hybrid Peptide Synthesis), and By End-User (Pharmaceutical & Biotechnology Companies, CROs & CDMOs, and Others), and Regional Forecast, 2026-2034

The global peptide synthesis services market size was valued at USD 1.02 billion in 2025. The market is projected to grow from USD 1.10 billion in 2026 to USD 1.93 billion by 2034, exhibiting a CAGR of 7.37% during the forecast period.

The global peptide synthesis services market is witnessing significant growth due to the increasing demand for peptide-based drugs and rising research and development activities by the research community and pharmaceutical & biotechnology companies, leading to increased adoption of these services.

• For instance, in January 2025, Cytovance Biologics partnered with PolyPeptide to address the increasing demand for peptide drugs. This collaboration aimed to leverage Cytovance's strengths in microbial and mammalian expression, process development, and cGMP manufacturing alongside PolyPeptide's expertise in the development and production of complex peptides.

Peptides are short chains of amino acids linked by amide bonds, crucial for maintaining homeostasis in living organisms. While natural peptide synthesis occurs in ribosomes, it is often insufficient for research and applications outside the body. Advancements in biotechnology enable the synthetic production of peptides on an industrial scale, allowing commercial peptide synthesis companies to create high-quality synthetic peptides for various uses.

Peptide Synthesis Services Market Driver

Rising Research and Development to Accelerate Peptide-Based Drug Discovery to Drive Market Growth

The increasing focus on research and development in the pharmaceutical industry is significantly accelerating peptide-based drug discovery, leading to increased demand for peptide synthesis services. Peptides, known for their specificity and efficacy, are becoming pivotal in treating various diseases, including cancer, metabolic disorders, and infectious diseases. The growing prevalence of chronic diseases and the rising demand for targeted therapies are compelling pharmaceutical companies to invest heavily in R&D, leading to the discovery of novel peptides with improved pharmacological properties.

Furthermore, advancements in peptide therapeutics and the increasing strategic activities amongst the companies to accelerate the peptide-drug discovery also boost the demand for peptide synthesis services.

• For instance, in September 2023, SPIMA Therapeutics announced an exclusive licensing agreement with SATT AxLR for SPM001. This stapled peptide is engineered to inhibit the Myddosome complex and boasts remarkable pharmacological characteristics, offering the potential to treat severe immunological disorders and aggressive cancers associated with MyD88 mutations. Such scenarios drive the market growth.

Estimated Number of New Cancer Cases Per Year Worldwide, 2022 & 2040, in Millions

According to the National Cancer Institute Cancer Statistics, an estimated 20.0 million new cases of cancer were registered in 2022, which is estimated to increase by 29.9 million new cases per year in 2040.

Peptide Synthesis Services Market Restraint

Lack of Clear Regulatory Infrastructure & Shortage of Skilled Labor Hinders Market Growth

The lack of a standard regulatory framework and skilled professionals for peptide synthesis is anticipated to limit the market growth to a certain extent during the forecast period. The peptide synthesis market operates within a complex landscape of regulations that can vary significantly by region. Inconsistent guidelines can lead to confusion among manufacturers and service providers, resulting in compliance challenges.

• For instance, according to an article published by American University in 2022, there are currently no internationally recognized best practices for safe and effective synthetic biology research.

Such scenarios may hinder the proper adoption of services for manufacturing high-quality peptides and limit the market growth.

Additionally, peptide synthesis requires specialized knowledge in chemistry, biochemistry, and advanced laboratory techniques. A shortage of skilled professionals in these areas can limit the capacity of companies to meet growing demand.

Peptide Synthesis Services Market Opportunity

Expansion of Peptide Synthesis Manufacturing Facilities to Cater Market Growth

In recent times, the increasing demand for peptides in pharmaceuticals, biotechnology, and research applications has offered substantial opportunities for companies to expand their peptide synthesis manufacturing facilities. By aligning with industry trends and investing in innovative technologies, peptide synthesis service providers can not only address current market demands but also position themselves for future growth. This scenario is ultimately contributing to advancements in healthcare and therapeutic development, and market growth.

• For instance, in January 2025, BioDuro, the contract research, development, and manufacturing organization, announced the establishment of a fully automated solid-phase peptide synthesis scale-up laboratory in Shanghai, China. This state-of-the-art facility is equipped with automated solid-phase peptide synthesizers, cleavage systems, and freeze-drying equipment aimed to fulfill the growing demand from global partners for efficient, scalable peptide manufacturing. Also, this facility produced a range of molecules, including both linear and cyclic peptides and peptide-drug conjugates. Such a launch of advanced facilities with large-scale production capabilities will propel the demand for the market during the forecast period.

Key Insights

The report covers the following key insights:

• Technological Developments in the Peptide Synthesis
• Key Industry Developments - Mergers, Acquisitions, Partnerships, Launches, etc. 
• Impact of COVID-19 on the Market

Segmentation

Analysis by Type 

By type, the market is divided into custom peptide synthesis, GMP peptide synthesis, and library peptide synthesis.

Custom peptide synthesis is expected to hold a significant share of the market. Increasing demand for cost-effective and high-quality peptides is driving the demand for custom peptide synthesis services. Additionally, key service providers are allowing easier and more convenient processes for ordering custom peptides to boost the growth of the segment in the market.

• For instance, in October 2023, Biosynth launched an automated peptide quotation tool for customers with a web account. This innovative tool enables users to quickly and easily generate custom peptide quotes, which are designed to be fast, flexible, and versatile. It allows customers to input peptide sequences in any format and select from various options for quantity, purity, and services. Such launches increase flexibility and promote the demand and growth of the market.

Analysis by Purity

By purity, the market is divided into crude, moderate (>70%), high (>95%), very high (>98%), and others.

The very high (>98%) is expected to hold a substantial portion of the market. There is an increasing demand for high-purity peptides for quantitative bioassays, quantitative in vitro receptor-ligand interaction studies, and various diagnostics and therapeutic applications, as slight impurities can impact biological activity, stability, and efficacy. Moreover, the rise in funding initiatives aimed at establishing innovative peptide manufacturing platforms is set to enhance the synthesis of large, high-purity peptides, thereby minimizing errors and driving growth in this segment. 

• For example, in December 2023, Amide Technologies secured USD 16.5 million in funding to launch its cutting-edge peptide manufacturing platform, which significantly broadens the prospects of peptide drug design. This platform enables the reliable linear synthesis of peptides containing up to 120 amino acids, a substantial advancement compared to the typical maximum of around 40 amino acids achieved by traditional SPPS technology. This innovation is expected to contribute to the expansion of the very high (>98%) purity market segment. 

Analysis by Technique

By technique, the market is divided into solid-phase peptide synthesis, liquid-phase peptide synthesis, and hybrid peptide synthesis.

Liquid-phase peptide synthesis is expected to grow significantly during the forecast period. The growth of the segment is driven by the increasing launch of novel liquid-phase peptide synthesis (LPPS) technology for manufacturing peptides.

• For instance, in September 2024, Cambrex announced its subsidiary Snapdragon Chemistry had created a novel liquid-phase peptide synthesis (LPPS) technology. The new LPPS technology significantly decreases solvent usage and minimizes the requirement for excess reagents in comparison to traditional solid-state peptide synthesis methods. Such advancements are expected to propel the growth of the segment during the forecast period.

Analysis by End-User

By end-user, the market is divided into pharmaceutical & biotechnology companies, CROs & CDMOs, and others.

The pharmaceutical & biotechnology companies held a considerable market share. The increasing adoption of synthesized peptide products by pharmaceutical and biotechnological companies to develop novel treatment options for different diseases leads to the market's growth. Additionally, increasing launches of services for these settings by the key players of the market are expanding the growth of the segment in the market.

• For instance, in May 2023, SynCrest Inc. announced that its service for peptide-based therapeutics is now accessible to pharmaceutical companies and research institutions across Japan, Europe, North America, and South America. Such scenarios are expected to boost the growth of the segment in the market.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for a substantial share of the global peptide synthesis services market in 2024. The region's growth is amplified by the increasing prevalence of cancer and infectious diseases, the presence of a favorable research and development environment, and rising initiatives to develop advanced and novel peptide therapeutics. Additionally, the presence of key market players with advanced service offerings is aimed at propelling the region's growth in the market.

• For instance, in December 2024, AbbVie acquired Nimble Therapeutics, which includes its lead investigational oral peptide IL23R inhibitor for psoriasis and a pipeline of other oral peptide candidates for autoimmune diseases. The acquisition also includes Nimble's proprietary peptide synthesis and optimization platform, designed for rapid discovery of peptide candidates. Such strategic activities propelled the region’s growth in the market.

On the other hand, Europe held a considerable share of the peptide synthesis services market. The growth of the region is due to the strong presence of key players and expanded focus on launching peptide therapeutics, which promote the growth of the market in the region.

• For instance, in September 2023, Biosynth acquired Pepceuticals, a UK-based manufacturer of synthetic peptides. Pepceuticals offers multi-kilogram GMP facilities and fill-finish capabilities, enabling them to support clients throughout the entire process, from clinical trials to commercial production. Such scenarios promote the growth of the region in the market.

Moreover, Asia Pacific is expected to grow notably during the forecast period. The growth of the region is attributed to the rising prevalence of chronic disease and the increasing demand for peptide synthesis services to develop new personalized treatments, discover drugs, and more.

Key Players Covered

The global peptide synthesis services market is fragmented, with a small number of groups and standalone providers. The report includes the profiles of the following key players:

• GenScript (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Biomatik (Canada)
• Aurigene Pharmaceutical Services Ltd. (India)
• Covalab, Inc. (U.K.)
• Protogenix (France)
• rPeptide (U.S.)

Key Industry Developments

• In March 2025, CordenPharma established a new peptide manufacturing facility in Switzerland. The facility aimed to deliver flexible and efficient peptide manufacturing to meet the growing demand for innovative peptide medicines.
• In August 2023, GenScript Biotech Corporation announced the expansion of its production of complex and modified peptides at its advanced cGMP manufacturing facility in Zhenjiang, China. The facility aimed to offer a comprehensive service that provides neoantigen and peptide active pharmaceutical ingredients (APIs) tailored for large-scale production.